Myeloma minimal residual disease testing in the United States: Evidence of improved standardization

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

(2015) Maria Arroz et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Assessment of minimal residual disease in myeloma and the need for a consensus approach

(2015) Andy C. Rawstron et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

(2015) Maryalice Stetler-Stevenson et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

(2014) Ola Landgren et al.   AMERICAN JOURNAL OF HEMATOLOGY

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

(2013) A. Flanders et al.   BLOOD

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY